Hørsholm, August 30, 2017
Today, Gubra announced the successful conclusion of a research collaboration with Sanofi, focusing on the discovery of novel gastrointestinal peptides that could potentially lead to the development of drugs for the treatment of diabetes and obesity. Concurring, Gubra achieved a further milestone by identifying such novel peptide and demonstrating fulfilment of certain predefined criteria. The collaboration between Sanofi and Gubra was built upon the research consortium between Gubra, Gentofte Hospital and The University of
Copenhagen started in 2012 which was partly funded by The Danish National Advanced Technology foundation.
“Throughout our four-year collaboration with Gubra we have been impressed by the quality of their work and their diligence. The achievement of this third research milestone reflects a great collaboration where all parties have contributed and benefitted. This has been a textbook example of a well-executed research collaboration for all parties involved”, says Philip Just Larsen, Senior Vice President and Global Head Diabetes Research and Translational Medicine at Sanofi.
“The collaboration has been instrumental in transforming Gubra from a relatively small company into a much more robust and diverse company with a broad portfolio of capabilities and a pipeline of discovery projects. The collaboration with Sanofi has been impeccable and we are very proud that we have been able to deliver such strong data and state-of-the-art research enabling us to meet the criteria for this milestone three. This collaboration clearly showed how big pharma, biotech and academia can work together efficiently towards a common goal”, says Henrik Blou, CEO at Gubra.
Contacts
Sofia Pitt Boserup
Lead Communication Partner
+45 41889586
[email protected]
About Gubra
Gubra is a privately held biotech company since 2008, headquartered in Denmark. The company is a science and technology driven company with two primary areas of business: Preclinical contract research services (CRO) and proprietary early target and drug discovery programs. Gubra’s primary focus is within the metabolic space (obesity, diabetes, NASH, CKD, CVD and diabetic complications) adding to this fibrotic disease areas such as IPF and IBD. Gubra specializes in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. High quality, scientific excellence, advanced digitalization, speed and solid teamwork, are key company traits which have established Gubra as a highly professional and competent partner in the market. Learn more at www.gubra.dk
The post Gubra reaches third research milestone under a collaboration agreement with Sanofi appeared first on Gubra.
